FLT3 and acute myeloid leukemia: In a recently published clinical study by our group, a small cohort of older/unfit patients with newly diagnosed FLT3 mutated AML were treated with HMA, venetoclax, and FLT3 inhibitor combination (triplet regimen) on a clinical trial.